Last €9.17 EUR
Change Today +0.032 / 0.35%
Volume 0.0
41L On Other Exchanges
Symbol
Exchange
Berlin
Continuous
As of 2:13 AM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

laboratorios farmaceuticos r (41L) Snapshot

Open
€9.00
Previous Close
€9.14
Day High
€9.17
Day Low
€9.00
52 Week High
03/7/14 - €10.04
52 Week Low
07/25/13 - €7.04
Market Cap
458.6M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
50.0M
EX-Date
07/3/14
P/E TM
--
Dividend
€0.16
Dividend Yield
1.75%
Current Stock Chart for LABORATORIOS FARMACEUTICOS R (41L)

Related News

No related news articles were found.

laboratorios farmaceuticos r (41L) Related Businessweek News

No Related Businessweek News Found

laboratorios farmaceuticos r (41L) Details

Laboratorios Farmacéuticos ROVI, S.A. engages in the research, development, in licensing, manufacturing, and marketing of small molecule and specialty biologic drugs in Spain and internationally. Its principal product includes Bemiparin, a low molecular weight heparin. The company’s prescription products comprise Hibor to prevent thromboembolic disease; Osseor to treat post-menopausal osteoporosis; Hepadren for the prevention of clotting in the extracorporeal circuit; Pneumovax-23, a vaccine for immunization against pneumococcal illness; Glufan for relieving symptoms of degenerative osteoarthritis; and Corlentor for treating chronic stable angina pectoris. Its prescription products also include Exxiv for relieving the symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylarthritis, and acute gouty arthritis; Calcio y Vitamina D3 ROVI to treat osteoporosis; Bertanel to treat adults active rheumatoid, juvenile idiopatic, and psoriatic arthritis; Vytorin for patients with primary hypercholesterolaemia or mixed hyperlipidaemia; Absorcol for patients with hypercholesterolaemia and phytosterolaemia; and Thymanax for treating depressive episodes in adults. In addition, the company offers diagnostic products, such as SonoVue contrast medium for use with ultrasound imaging; and Iopamiro and Iomeron contrast media for diagnosis by computed tomography; and Multihance And Prohance for use in diagnostic magnetic resonance imaging, as well as OTC products comprising Perspirex to control sweating from the armpits; Enerzone, a protein product; Dentimelo to repair oral mucosal lesions and gums; and ColdPack cold and hot bag for reliving pain. Further, it distributes products licensed from other laboratories. The company was founded in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmacéuticos ROVI, S.A. is a subsidiary of Inversiones Clidia, S.L.

Founded in 1946

laboratorios farmaceuticos r (41L) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €398.0K
Chairman of The Board, Chief Executive Office...
Total Annual Compensation: €233.0K
Chief Financial Officer, Director and Member ...
Total Annual Compensation: €293.0K
Director of Corporate Development and Directo...
Total Annual Compensation: €293.0K
Compensation as of Fiscal Year 2012.

laboratorios farmaceuticos r (41L) Key Developments

Laboratorios Farmaceuticos ROVI, S.A. Presents at 10th Foro MedCap, May-27-2014

Laboratorios Farmaceuticos ROVI, S.A. Presents at 10th Foro MedCap, May-27-2014 . Venue: Palacio de la Bolsa, Plaza de la Lealtad, 1, 28014 Madrid, Spain.

Laboratorios Farmaceuticos ROVI, S.A., Annual General Meeting, Jun 12, 2014

Laboratorios Farmaceuticos ROVI, S.A., Annual General Meeting, Jun 12, 2014.

Laboratorios Farmaceuticos ROVI, S.A. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Operating Revenue Guidance for the Year 2014

Laboratorios Farmaceuticos ROVI, S.A. reported consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported revenue of EUR 57.624 million compared to EUR 53.781 million a year ago. Operating profit was EUR 6.887 million compared to EUR 5.988 million a year ago. Profit before income tax was EUR 6.231 million compared to EUR 5.510 million a year ago. Profit for the year was EUR 5.930 million compared to EUR 5.338 million a year ago. Net cash used in operating activities was EUR 3.557 million compared to net cash generated from operating activities of EUR 6.092 million a year ago. Purchases of intangible assets were EUR 0.268 million compared to EUR 0.120 million a year ago. Purchases of property, plant and equipment was EUR 1.388 million compared to EUR 1.386 million a year ago. The company expects a mid-to-high single-digit growth rate in operating revenue for 2014. The company expects capital expenditure for 2014 to be below the 2013 figure of EUR 24.7 million, but above the 2012 level of EUR 13.7 million due to the investments related to the Risperidone-ISM® project.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
41L:GR €9.17 EUR +0.032

41L Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 41L.
View Industry Companies
 

Industry Analysis

41L

Industry Average

Valuation 41L Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 14.6x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LABORATORIOS FARMACEUTICOS R, please visit www.rovi.es. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.